Clinical Forms

Disease Activity & Damage IndexesBack to Top

Rheumatoid Arthritis Disease Activity Measures

The ACR has developed new recommendations for RA Disease Activity Measures which will be published in the May 2012 issue of Arthritis Care & Research.

Other Indexes

  • SLICC/ACR Damage Index
    The SLICC/ACR Damage Index for SLE was developed and validated to measure accumulated organ damage from either the disease process or its sequelae, in 12 organ systems. It is an important predictor of long-term mortality and is an independent outcome measure separate from the SLEDAI. Although not formally evaluated in children, it has been used in descriptive studies of pediatric SLE. Only nonreversible change that has occurred since the onset of SLE is to be included, rather than change related to active inflammation.
    Access SLICC/ACR Damage Index.
  • SLEDAI SLE Disease Activity Index
    The original SLEDAI is a weighted, cumulative index of lupus disease activity, and the SELENA SLEDAI represents a further refinement. The total score falls between 0 and 105, with higher scores representing increased disease activity. The SLEDAI has been shown to be a valid and reliable disease activity measure in multiple patient groups, and has also has been shown to be sensitive to changes in disease activity in children.
    Access SLEDAI SLE Disease Activity Index.
  • Bath Anklosing Spondylitis Disease Activity Index from a member; requires login

AssessmentsBack to Top

This page presents adult and pediatric rheumatology health status assessments.

Please login to see the members-only version of this page. Items submitted by members have been provided voluntarily for other members to make use of in their practices.

Adult Assessment

  • Health Assessment Questionnaire from a member; requires login
  • Multidimensional Health Assessment Questionnaire requires login

Pediatric Assessments

  • CHAQ
    The Childhood Health Assessment Questionnaire is a pediatric modification of the Stanford Health Assessment Questionnaire (HAQ). It has been shown to be a valid and sensitive tool in the evaluation of functional outcomes in children with chronic arthritis, and is a component of the validated JRA core set criteria used to measure improvement and flare in clinical trials. The CHAQ has been translated and validated in numerous languages. The scoring technique and range of possible scores (0-3) is the same as the HAQ. Developed and copyrighted by Gurkipal Singh, MD. Permission for use must be granted by the copyright holder.
  • CMAS
    The Childhood Myositis Assessment Scale was developed to assess muscle function in the areas of strength and endurance across a wide range of ability and ages in children with Juvenile dermatomyositis (JDM) and polymyositis The 14 ordinal items included were chosen to assess primarily axial and proximal muscle groups and are ranked with standard performance and scoring methods. The CMAS has a potential range of 0-52 with higher scores indicating greater muscle strength and endurance. CMAS scoring sheet. Developed by Robert Rennebohm, MD.
  • JAFAR
    The Juvenile Arthritis Functional Assessment Report is a questionnaire to measure functional ability in children with JRA/JIA that can be completed by either parents (JAFAR-P) or patients (JAFAR-C). The validated subject age range is 7-18 years. 23 activities of daily function are included and responses reflect child's ability to independently perform the activity in the past week (0=all the time, 1 = some of the time, 2 = almost never). The theoretical score range is 0-46 with increasing scores indicating worse function. Developed by Daniel J. Lovell, MD, MPH.
  • JAQQ
    Developed by Ciarán M Duffy, MB BCh MSc FRCPC.
  • The Peds QL™ can be ordered through the Mapi Research Institute's Web site. It has generic and disease-specific modules designed to measure health related quality of life (HRQOL) dimensions in pediatrics. The PedsQL™ 4.0 Generic Core Scales were designed as a generic HRQOL instrument across diverse pediatric populations, and include child self-report for ages 5-18 and parent proxy-report for ages 2-18. The PedsQL™ 3.0 Rheumatology Module was designed to measure HRQOL dimensions specifically tailored for pediatric rheumatology.